- Conditions
- B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, T Acute Lymphoblastic Leukemia
- Interventions
- Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Collection, Computed Tomography, Cyclophosphamide, Doxorubicin, Etoposide, Filgrastim, Pegfilgrastim, Positron Emission Tomography, Prednisone, Rituximab, Vincristine
- Drug · Procedure · Biological
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Seattle, Washington
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 793–816
of 1,851
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus-Related Neck Squamous Cell Carcinoma of Unknown Primary, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma, Metastatic Nasopharyngeal Squamous Cell Carcinoma, Metastatic Oral Cavity Squamous Cell Carcinoma, Metastatic Oropharyngeal Squamous Cell Carcinoma, Metastatic Paranasal Sinus Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Nasopharyngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Recurrent Paranasal Sinus Squamous Cell Carcinoma, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Lip and Oral Cavity Cancer AJCC v8, Stage IV Nasopharyngeal Carcinoma AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IV Sinonasal Cancer AJCC v8
- Interventions
- Biospecimen Collection, Computed Tomography, Lovastatin, Magnetic Resonance Imaging, Pembrolizumab, Positron Emission Tomography
- Procedure · Drug · Biological
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
- Conditions
- Healthy Volunteer
- Interventions
- [18F]MNI-444
- Drug
- Lead sponsor
- Invicro
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Uterine Cancer
- Interventions
- 18F-Fluoroestradiol
- Drug
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Soft Tissue Sarcoma
- Interventions
- Biopsy, Biospecimen Collection, Computed Tomography, Positron Emission Tomography, Propranolol, Radiation Therapy, Surgical Procedure
- Procedure · Drug · Radiation
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Healthy
- Interventions
- EVP-6308
- Drug
- Lead sponsor
- FORUM Pharmaceuticals Inc
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2013
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Metastatic Malignant Neoplasm in the Brain, Primary Brain Neoplasm, Recurrent Brain Neoplasm
- Interventions
- Computed Tomography, Fluorothymidine F-18, Positron Emission Tomography
- Procedure · Radiation
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Myocardial Blood Flow Reserve
- Interventions
- Regadenoson, Rubidium-82
- Drug · Radiation
- Lead sponsor
- Timothy M. Bateman, MD
- Industry
- Eligibility
- 40 Years to 65 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Kansas City, Missouri
- Conditions
- Frontotemporal Dementia
- Interventions
- Flortaucipir F18, Brain PET scan
- Drug · Procedure
- Lead sponsor
- Avid Radiopharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 3
- States / cities
- La Jolla, California • San Francisco, California • Dallas, Texas
- Conditions
- Indolent B-Cell Non-Hodgkin Lymphoma, Recurrent Indolent B-Cell Non-Hodgkin Lymphoma, Refractory Indolent B-Cell Non-Hodgkin Lymphoma, Recurrent Indolent Non-Hodgkin Lymphoma, Refractory Indolent Non-Hodgkin Lymphoma
- Interventions
- Computed Tomography, Endoscopic Procedure, Involved-site Radiation Therapy (3 Fractions), Involved-site Radiation Therapy (12 Fractions), Positron Emission Tomography, Questionnaire Administration
- Procedure · Radiation · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 7
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Albert Lea, Minnesota + 4 more
- Conditions
- Skin Angiosarcoma, Skin Radiation-Related Angiosarcoma, Visceral Angiosarcoma
- Interventions
- Biospecimen Collection, Cabozantinib S-malate, Computed Tomography, FDG-Positron Emission Tomography, Magnetic Resonance Imaging, Nivolumab, Paclitaxel, Quality-of-Life Assessment, Questionnaire Administration
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 170
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 120 more
- Conditions
- Normal Human Subjects
- Interventions
- Not listed
- Lead sponsor
- Amen Clinics, Inc.
- Industry
- Eligibility
- 10 Years to 90 Years
- Enrollment
- 97 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2010
- U.S. locations
- 1
- States / cities
- Newport Beach, California
- Conditions
- Locally Advanced Gastrointestinal Stromal Tumor, Locally Advanced Sarcoma, Metastatic Gastrointestinal Stromal Tumor, Metastatic Sarcoma, Stage III Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8, Stage III Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8, Stage IV Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8, Stage IV Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8
- Interventions
- Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Rogaratinib
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 18
- States / cities
- Duarte, California • Irvine, California • Aurora, Colorado + 13 more
- Conditions
- Carcinoma, Squamous Cell of Head and Neck
- Interventions
- PET/CT, Computed Tomography (CT)
- Other
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Alzheimer's Disease, Healthy
- Interventions
- [11C]MeS-IMPY
- Drug
- Lead sponsor
- National Institute of Mental Health (NIMH)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2006
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Healthy Volunteers, Nicotine Dependence, Pharmacokinetics
- Interventions
- Not listed
- Lead sponsor
- National Institute on Drug Abuse (NIDA)
- NIH
- Eligibility
- 21 Years to 45 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Ventricular Tachycardia
- Interventions
- [C-11] Meta-hydroxyephedrine radioactive tracer (MHED)
- Drug
- Lead sponsor
- Khaled Awad, MD
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent Primary Mediastinal Large B-Cell Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Grade 3b Follicular Lymphoma, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified, Refractory Primary Mediastinal Large B-Cell Lymphoma, Refractory Transformed Non-Hodgkin Lymphoma
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Epcoritamab, Ibrutinib, Positron Emission Tomography
- Procedure · Biological · Drug
- Lead sponsor
- Yazeed Sawalha
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 3
- States / cities
- Minneapolis, Minnesota • Columbus, Ohio • Richmond, Virginia
- Conditions
- Healthy Volunteers
- Interventions
- Brain Imaging (PET), Aterial Line, Blood Sampling
- Procedure
- Lead sponsor
- National Institute of Mental Health (NIMH)
- NIH
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma
- Interventions
- Bone Marrow Biopsy, Cyclophosphamide, Doxorubicin, Prednisone, Retifanlimab, Rituximab and Hyaluronidase Human, Tafasitamab, Vincristine, Bone Marrow Aspiration, Multigated Acquisition Scan, Fludeoxyglucose F-18, Positron Emission Tomography, Computed Tomography, Biospecimen Collection, Polatuzumab Vedotin
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Healthy Participants, Idiopathic Pulmonary Fibrosis (IPF)
- Interventions
- 18F-BMS-986327
- Diagnostic Test
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma, Stage IV Colon Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Rectal Cancer AJCC v8
- Interventions
- Balstilimab, Bevacizumab, Biospecimen Collection, Botensilimab, Computed Tomography, Fluorouracil, Leucovorin Calcium, Magnetic Resonance Imaging, Oxaliplatin, Positron Emission Tomography, X-Ray Imaging
- Biological · Procedure · Drug
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Interstitial Lung Disease
- Interventions
- [68Ga]CBP8, Dotarem
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Alzheimer Disease, Healthy Aging
- Interventions
- 11C-PiB
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2022
- U.S. locations
- 1
- States / cities
- Aurora, Colorado